Precision Neuroscience Secures $93M to Advance Minimally Invasive BCI Technology
Summary
Precision Neuroscience, a New York-based developer specializing in brain-computer interfaces (BCI), has successfully raised $93 million in a Series C funding round, according to a recent financial filing. This latest round, disclosed through the Securities and Exchange Commission, forms part of the companys ambition to raise up to $150 million, with participation from 21 investors. With this round, Precision Neurosciences total funding to date reaches approximately $146 million.Founded by Chief Science Officer Dr. Ben Rapoport, a former Neuralink co-founder, and CEO Michael Mager, Precision Neuroscience is pioneering its Layer 7 Cortical Interface, a flexible, ultra-thin implant designed to map brain activity with high resolution. This technology is crafted for a unique implantation procedure that bypasses traditional craniotomies, utilizing a micro-slit technique involving 400-micron-wide incisions. With plans to deploy its device in clinical settings next year, the company aims to bring this advanced interface to market following regulatory approvals.